Skip to main content
Equibles

Kirsten Flowers

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Kirsten Flowers

Kirsten Flowers was last confirmed as Board Member at PMV Pharmaceuticals, Inc. (PMVP) in a filing dated April 25, 2025. Kura Oncology, Inc. reported in an 8-K filed January 13, 2023 that Kirsten Flowers resigned as Chief Commercial Officer, effective January 27, 2023. The proxy statement of Kura Oncology, Inc. reports total compensation of $2,500,538 for Kirsten Flowers in fiscal 2022, including a base salary of $466,250. Disclosed compensation is on record for 3 fiscal years.

“On January 10, 2023, Kirsten Flowers notified Kura Oncology, Inc. (the "Company") of her intention to resign from her position as the Company's Chief Commercial Officer, effective as of January 27, 2023 (the "Separation Date"), in order to pursue other opportunities.”
Kura Oncology, Inc. Form 8-K, filed January 13, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Kura Oncology, Inc. (KURA) $466,250 $2,500,538
2021 Kura Oncology, Inc. (KURA) $442,000 $3,289,353
2020 Kura Oncology, Inc. (KURA) $420,368 $2,948,392

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.